Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 2 , Pages 53-65 , June 2006

Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems

  • Catarina Pinto Reis, MS

      Affiliations

    • Laboratorio Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Coimbra, Portugal
    • ,
  • Ronald J. Neufeld, PhD

      Affiliations

    • Department of Chemical Engineering, Queen's University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Chemical Engineering Department, Dupuis Hall, Queen's University, Kingston, Ontario, Canada, K7L3N6.
    • ,
  • António J. Ribeiro, PhD

      Affiliations

    • Depart. Tecnologia Farmacêutica, I. S. C. S. N.-C. E. S. P. U., Gandra, Paredes, Portugal
    • ,
  • Francisco Veiga, PhD

      Affiliations

    • Laboratorio Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Coimbra, Portugal

Received 10 April 2006 ,Accepted 12 April 2006.

References 

  1. Li Y-P, Pei Y-Y, Zhang X-Y, Gu Z-H, Zhou Z-H, Yuan W-F, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Contr Rel. 2001;71:203–211
  2. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, et al. Binding and uptake of biodegradable poly-d,l-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci. 1998;6:153–163
  3. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Rel. 2001;70:1–20
  4. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93:1980–1992
  5. TenHoor C, Dressman J. Oral absorption of peptides and proteins. S.T.P. Pharma Sci. 1992;2:301–312
  6. Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S, Amidon GL, et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J Contr Rel. 1997;46:39–57
  7. Adibi SA, Kim YS. Peptide absorption and hydrolysis. In:  Johnson LR editors. Physiology of the gastrointestinal tract. New York: Raven Press; 1981;p. 1073–1095
  8. Bohley P, Seglen PO. Proteases and proteolysis in the lysosome. Experientia. 1992;151–157
  9. Drasar BS, Hill MJ. Bacterial glycosidase. In:  Drasar BS,  Hill MJ editor. Human intestinal flora. London: Academic Press; 1974;p. 54–71
  10. Fix JA. Oral Contrled release technology for peptides: status and future prospects. Pharm Res. 1996;13:1760–1764
  11. Zhou XH. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J Contr Rel. 1994;29:239–252
  12. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Contr Rel. 1994;29:253–267
  13. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Del Rev. 1993;10:141–162
  14. Lee VHL, Dodda-kashi S, Grass OM, Rubas W. Oral route of peptide and protein drug delivery. In:  Lee VHL editors. Protein and peptide drug delivery. New York: Marcel Dekker; 1991;p. 691–738
  15. Fukunaga M, Miller MM, Deftos LJ. Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats. Horm Metab Res. 1991;23:166–167
  16. Silva Cunha A, Grossiord JL, Puisieux F, Seiller M. Insulin in w/o/w multiple emulsions: preparation, characterization and determination of stability towards proteases in vitro. J Microencapsulation. 1997;14:311–319
  17. Matsuzawa A, Morishita M, Takayama K, Nagai T. Absorption of insulin using water-in-oil-in-water emulsion from enteral loop in rats. Biol Pharm Bull. 1995;18:1718–1723
  18. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm. 1992;78:9–16
  19. Allémann E, Leroux JC, Gurny R. Polymeric nano-microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Del Rev. 1998;34:171–189
  20. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm. 1995;41:2–13
  21. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev. 2003;55:329–347
  22. Jaehere FD, Doelker E, Gurny R. Nanoparticles. In:  Mathiowitz E editors. Nanoparticles. New York: Wiley and Son, Inc; 1999;p. 641–664
  23. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by rat gastrointestinal mucosa: quantitation and particles size dependency. J Pharm Pharmacol. 1990;42:821–826
  24. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Contr Rel. 1990;11:205–214
  25. Michel C, Aprahamian M, Defontaine L, Couvreur P, Damgé C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol. 1991;43:1–5
  26. Damgé C, Aprahamian M, Humbert W, Pinget M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J Pharm Pharmacol. 2000;52:1049–1056
  27. Kreuter J, Muller U, Munz K. Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int J Pharm. 1989;55:39–45
  28. Aprahamian M, Michel C, Humbert W, Devissaguet J-P, Damgé C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell. 1987;61:69–76
  29. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Del Rev. 2003;55:519–548
  30. Florence AT. The oral absorption of micro and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14:259–266
  31. Hussain N. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Del Rev. 2001;50:107–142
  32. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur J Pharm Biopharm. 2000;50:147–160
  33. Couvreur P. Polyalkylcyanoacrylates as colloidal drug carriers. Crit Rev Ther Drug Carrier Syst. 1988;5:1–20
  34. Allémann E, Gurny R, Doekler E. Drug-loaded nanoparticles—preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993;39:173–191
  35. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly (lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22:2406–2412
  36. Couvreur P, Lenaerts V, Kante B, Roland M, Speiser PP. Oral and parenteral administration of insulin associated to hydrolyzable nanoparticles. Acta Pharm Technol. 1980;26:220–222
  37. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Contr Rel. 1995;36:39–46
  38. Jani P, Florence AT, McCarthy DE. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm. 1992;84:245–252
  39. Jani P, McCarthy DE, Florence AT. Nanosphere and microsphere uptake via Peyer's patches: observation on the rate of uptake in the rat after a single oral dose. Int J Pharm. 1992;86:239–246
  40. Allémann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int J Pharm. 1992;87:247–253
  41. Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet J-P, Maincent P. The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res. 1991;8:734–738
  42. Espuelas MS, Legrand P, Irache JM, Gamazo C, Orecchioni A-M, Devissaguet J-P, et al. Poly(ɛ-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm. 1997;158:19–27
  43. Fessi H, Puisieux F, Devissaguet J-P, Ammoury N, Benita S. Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm. 1989;55:R1–R4
  44. Ammoury N, Fessi H, Devissaguet J-P, Dubrasquet M, Benita S. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res. 1991;8:101–105
  45. Grangier JL, Puygrenier M, Gauthier JC, Couvreur P. Nanoparticles as carriers for growth hormone releasing factors (GRF). J Contr Rel. 1991;15:3–13
  46. Roques M, Damgé C, Michel C, Staedel C, Crémel G, Hubert P. Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes. 1992;41:451–456
  47. Hirai S, Ikenaga T, Matsuzawa T. Nasal absorption of insulin in dogs. Diabetes. 1978;27:296–299
  48. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233:1081–1084
  49. Cho YW, Flynn M. Oral delivery of insulin. Lancet. 1989;2:1518–1519
  50. Patel HM, Ryman BE. Oral administration of insulin by encapsulation within liposomes. FEBS Lett. 1976;62:60–63
  51. Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes. 1988;37:246–251
  52. Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J Biomed Mater Res. 1999;47:568–576
  53. Aboubakar M, Couvreur P, Pinto-Alphandary H, Gouritin B, Lacour B, Farinotti R, et al. Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation. Drug Dev Res. 2000;49:109–117
  54. Oppenheim RC, Stewart NF, Gordon L, Patel HM. Production and evaluation of orally administered insulin nanoparticles. Drug Dev Ind Pharm. 1982;8:531–546
  55. Watnasirichaikul S, Davies NM, Rades T, Tucker IG. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm Res. 2000;17:684–689
  56. Al Khouri N, Roblot-Treupel L, Fessi H, Devissaguet J-P, Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm. 1986;28:125–132
  57. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet J-P. Nanocapsules as carriers for oral peptide delivery. J Contr Rel. 1990;13:233–239
  58. Pinto-Alphandary H. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res. 2003;207:1071–1084
  59. Michel C, Defontaine L, Aprahamian M, Couvreur P, Damgé C. Insulin nanocapsules: variations in the biological response depending on the administration site along the digestive tract. In:  Whateley TL editors. Microencapsulation of drugs. Chur, Switzerland: Hardwood Academic Publishers; 1992;p. 233–242
  60. Damgé C, Vonderscher J, Marbach P, Pinget M. Poly(alkylcyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol. 1997;49:949–954
  61. Michel C, Roques M, Couvreur P, Vranchx H, Baldschmidt P. Isobutylcyanoacrylate nanoparticles as drug carrier for oral administration of insulin. Proc Int Symp Contr Rel Bioact Mater. 1991;18:97–98
  62. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T. Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation. Int J Pharm. 1992;78:1–7
  63. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chichering DE, Chaturverdi P, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature. 1997;386:410–414
  64. Watnasirichaikul S, Rades T, Tucker IG. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J Pharm Pharmacol. 2002;54:473–480
  65. Elvassore N, Bertucco A, Caliceti P. Production of insulin-loaded poly(ethylene glycol)/poly(l-lactide) (PEG/PLA) nanoparticles by gas antisolvent techniques. J Pharm Sci. 2001;90:1628–1636
  66. Gomez A, Bingham D, Juan L, Tang K. Production of protein nanoparticles by electrospray drying. J Aerosol Sci. 1998;29:561–574
  67. Pan Y, Li Y, Zhao H, Zheng J, Xu H, Wei G, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm. 2002;249:139–147
  68. Sullivan CO, Birkinshaw C. In vitro degradation of insulin-loaded poly(n-butylcyanoacrylate) nanoparticles. Biomaterials. 2004;25:4375–4382
  69. Hillery AM, Toth I, Shaw AJ, Florence AT. Co-polymerized peptide particles (CPP) I: synthesis, characterization and in vitro studies on a novel oral nanoparticulate delivery system. J Contr Rel. 1996;41:271–281
  70. Hillery AM, Toth I, Florence AT. Co-polymerized peptide particles II: oral uptake of a novel co-polymeric nanoparticulate delivery system for peptides. J Contr Rel. 1996;42:65–73
  71. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005;296:122–132
  72. Allémann E, Leroux J-C, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Del Rev. 1998;34:171–189
  73. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J Pharm Pharmacol. 1994;46:547–552
  74. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive d,l-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of calcitonin. Pharm Dev Technol. 2000;5:77–85
  75. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Akashi M, et al. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm. 1997;149:93–106
  76. Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J Pharm Sci. 1996;85:206–213
  77. Murray JC, Carmichael J. Targeting solid tumours: challenges, disappointments, and opportunities. Adv Drug Del Rev. 1995;17:117–127
  78. Dubernet C, Fattal E, Couvreur P. Nanoparticulate controlled release system for cancer therapy. In:  Wise DL editors. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker; 2000;p. 287–300
  79. Gipps EM, Arshady R, Kreuter J, Groscurth P, Speiser PP. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J Pharm Sci. 1986;75:256–258
  80. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser PP. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm. 1983;15:335–345
  81. Groscurth P, Gipps E, Kreuter J. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. In:  Rygaard JR,  Brünner N,  Graem N,  Spang-Thomsen M editor. Immune-deficient animals in biomedical research. Basel: Karger; 1987;p. 401
  82. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev. 2001;47:65–81
  83. Das D, Lin S. Double-coated poly(butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci. 2005;94:1343–1353
  84. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood–brain barrier. Peptides. 1998;19:777–780
  85. Holmgren J, Lycke N. Immune mechanisms in enteric infections. In:  Holmgren J,  Linderberg A,  Molby RE editor. Development of vaccines and drugs against diarrhea. Bromley, UK: Studenlitteratur; 1986;p. 9–22
  86. Walker RI, Owen RL. Intestinal barriers to bacteria and their toxins. Annu Rev Med. 1988;41:393–400
  87. O'Hagan DT, Palin KJ, Davis SS. Intestinal absorption of proteins and macromolecules and the immunological response. Crit Rev Ther Drug Carrier Syst. 1987;4:197–220
  88. Gilligan CA, Po LW. Oral vaccines: design and delivery. Int J Pharm. 1991;75:1–24
  89. Ma L. DNA vaccines: a review. J Intern Med. 2003;253:402–410
  90. Strannegard O, Yurchison A. Formation of agglutinating and reagenic antibodies in rabbits following oral administration of soluble and particulate antigens. Int Arch Allergy Immunol Appl. 1969;35:579–590
  91. Cox DS, Taubman MA. Oral induction of the secretory antibody response by soluble and particulate antigens. Int Arch Allergy Immunol Appl. 1984;75:126–131
  92. Jeurisson SHM, Kraal G, Sminia T. The role of Peyer's patches in intestinal humoral immune responses is limited to memory formation. Adv Exp Med Biol. 1987;216A:257–265
  93. Birrenbach G, Speiser PP. Polymerized micelles and their use as adjuvants in immunology. J Pharm Sci. 1976;65:1763–1766
  94. Kreuter J, Mauler R, Gruschkau H, Speiser PP. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp Cell Biol. 1976;44:12–19
  95. Calvo P, Remuñán-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;14:1431–1436
  96. Frey A, Neutra MR, Robey FA. Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp 120. Bioconjug Chem. 1997;8:424–433
  97. Jani P, Florence AT, McCarthy D. Polystyrene nanosphere and microsphere uptake and translocation via the gut mucosa after a single oral dose. J Pharm Pharmacol. 1991;43(Suppl):27
  98. Yu WP, Barrat G, Devissaguet J-P, Puisieux F. Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-chol) entrapped in nanocapsules. Int J Immunopharmacol. 1991;13:167–173
  99. Seyler I, Appel M, Devissaguet J-P, Legrand P, Barratt G. Macrophage activation by a lipophilic derivative of muramyldipeptide within nanocapsules: investigation of the mechanism of drug delivery. J Nanoparticle Res. 1999;1:91–97
  100. Chen Y, Mohanraj VJ, Parkin JE. Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. Lett Peptide Sci. 2003;10:621–629
  101. Gautier JC, Grangier JL, Barbier A, Dupont P, Pastor G, Couvreur P. Biodegradable nanoparticles for subcutaneous administration of growth hormone releasing factor (hGRF). J Contr Rel. 1992;20:67–78
  102. Gurny R, Banker GS, Buri P. Développment d'un injectable de testostérone à action prolongée à base de latex biodégradable. Proc III Congr Hispano-français Biopharm Pharmacocin. 1979;173–179
  103. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohenc F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318
  104. Gurny R, Taylor D. Development and evaluation of a prolonged acting drug delivery system for the treatment of glaucoma. In:  Rubinstein MHE editors. Proceedings of the International Symposium of the British Pharmaceutical Technology Conference—Solid Dosage Research Unit. Liverpool. 1980;
  105. Calvo P, Sánchez A, Martinez J, López MI, Calonge M, Pastor JC, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res. 1996;13:311–315
  106. Zimmer A, Kreuter J, Robinson JR. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsulation. 1991;8:497–504
  107. Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA, et al. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study. J Microencapsulation. 1997;14:457–467
  108. Campos AMD, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159–168
  109. Campos AMD, Diebold Y, Carvalho ELS, Sánchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21:803–810
  110. Lee VHK, Wood RW, Kreuter J, Harmia T, Robinson JR. Ocular drug delivery of progesterone using nanoparticles. J Microencapsulation. 1986;3:213–218
  111. Diepold R, Kreuter J, Guggenbuhl P, Robinson JR. Distribution of poly-hexyl-2-cyano [3-14C]acrylate nanoparticles in healthy and chronically inflamed rabbit eyes. Int J Pharm. 1989;54:149–153
  112. Diepold R, Kreuter J, Himber J, Gurny R, Lee VH, Robinson JR, et al. Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles). Graefes Arch Clin Exp Ophthalmol. 1989;227:188–193
  113. Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Contr Rel. 2003;86:131–144
  114. McCallion ON, Taylor KM, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res. 1995;12:1682–1688
  115. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm. 2004;57:1–8
  116. Bridges PA, Taylor KM. Nebulizers for the generation of liposomal aerosols. Int J Pharm. 1998;173:117–152
  117. Leung KKM, Bridges PA, Taylor KMG. The stability of liposomes to ultrasonic nebulization. Int J Pharm. 1996;145:95–102
  118. Weiner N, Williams N, Birch G, Ramachandran C, Shipman CJ, Flynn G. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea-pig model. Antimicrob Agents Chemother. 1989;33:1217–1221
  119. Shim J, Kang HS, Park W-S, Han S-H, Kim J, Chang I-S. Transdermal delivery of minoxidil with block copolymer nanoparticles. J Contr Rel. 2004;97:477–484
  120. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16:1576–1581
  121. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res. 2002;19:998–1008
  122. Cui Z, Mumper RJ. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol. 2002;54:1195–1203
  123. Tobio M, Gref R, Sánchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res. 1998;15:270–275
  124. Schaffazick SR, Guterres SS, Freitas LL, Pohlmann AR. Caracterização e estabilidade fîsico-quimica de sistemas poliméricos nanoparticulados para administração de fármacos. Química Nova. 2003;26:726–737
  125. Dorkoosh FA, Verhoef JC, Rafiee-Tehrani M, Borchard G, Junginger HE. Peroral drug delivery systems for peptides and proteins. S.T.P. Pharma Sci. 2002;12:213–221
  126. Murillo M, Espuelas S, Prior S, Vitas AI, Renedo MJ, Goni MM, et al. Controlled liberation of active principles by means of new galenic formulations. Rev Med Univ Navarra. 2001;45:19–34
  127. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000;21:1–7
  128. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumours using vascular endothelial growth factor. Cancer Res. 1999;59:4129–4135
  129. Lemoine D, Préat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Contr Rel. 1998;54:15–27
  130. Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 1998;58:3385–3390
  131. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Del Rev. 1998;34:191–219
  132. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, et al. Magnetic resonance contrast enhancement of neovasculture with α(v)-β-(3)-targeted nanoparticles. Magn Reson Med. 2000;44:433–439
  133. Schaertl S, Meyer-Almes FJ, López-Calle E, Siemers A, Kramer PA. A novel and robust homogeneous fluorescence-based assay using nanoparticles for pharmaceutical screening and diagnostics. J Biomol Screen. 2000;5:227–238
  134. Perrin A, Theretz A, Lanet V, Vialle S, Mandrand B. Immunomagnetic concentration of antigens and detection based on scanning force microscopic immunoassay. J Immunol Methods. 1999;224:77–87
  135. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August JT, et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys. 1999;361:47–56

 No financial conflict of interest was reported by the authors of this paper.

PII: S1549-9634(06)00049-9

doi: 10.1016/j.nano.2006.04.009

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 2 , Pages 53-65 , June 2006

Article Tools

* Image Usage & Resolution